[15-year experience of  moxifloxacin in the treatment of patients with bacterial rhinosinusitis].
The article summarizes 15 years of experience of the use of moxifloxacin (Avelox) in Russia in patients with acute bacterial rhinosinusitis. Emphasize its high bactericidal activity against a broad spectrum of microorganisms- from basic agents to the atypical and anaerobic microflora. The results of these studies suggest the continued effectiveness of the dosage of 400 mg a short course (7 days) over 15 years of practical use of the drug, which in its clinical efficacy is superior to amoxicillin/clavulanate, cefuroxime axetil and levofloxacin. The safety profile of moxifloxacin, studied at the population level is not associated with an increased risk of adverse effects in compliance with the dosing regimen, taking into account the indications and contraindications.
Evdokimov Moscow State Medical Stomatological University, Moscow, Russia, 127473.
A Y
AY
Ovchinnikov
Evdokimov Moscow State Medical Stomatological University, Moscow, Russia, 127473.
M A
MA
Edzhe
Evdokimov Moscow State Medical Stomatological University, Moscow, Russia, 127473.
N A
NA
Miroshnichenko
Evdokimov Moscow State Medical Stomatological University, Moscow, Russia, 127473.
E M
EM
Hon
Sechenov First Moscow State Medical University, Moscow, Russia, 127018.
S A
SA
Korostelev
D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001424:Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D000077266:Moxifloxacin; D012220:Rhinitis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D012426:Russia; D012852:Sinusitis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077266:Moxifloxacin